On September 10, ZAI LAB fell 5.1% in regular trading, trading at HK$18.98, with turnover of approximately HK$91.85 million.

The decline reflects continued market digestion of the company's interim results. ZAI LAB reported first-half total revenue of US$206 million, down 5% year-over-year, while net loss widened 14% to US$102 million. Product revenue declined 6% to US$201 million, primarily due to lower sales of Zejula — pressured by generic olaparib entering centralized procurement — and a price reduction in Vyvgart linked to national insurance directory renewal. These headwinds were only partially offset by growth in Qinlock and NUZYRA. Meanwhile, R&D expenses rose 14% to US$127 million, further weighing on profitability. Basic and diluted loss per share increased to US$0.09 from US$0.08 a year earlier.

Adding to the stock-specific pressure, the broader biotechnology sector traded sharply lower on the day. Among peers, EVEREST MED fell 8.2%, 3SBIO declined 3.84%, INNOVENT BIO dropped 3.31%, AKESO lost 1.32%, and BEONE MEDICINES slipped 0.86%, amplifying the sell-off across the sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)